News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ICON: Pfizer Inc. (PFE) And Roche (RHHBY) Join ADDPLAN DF Consortium


8/1/2014 10:08:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), today announced that Pfizer and Roche have joined the ADDPLAN® DF Consortium. The consortium was founded in 2013 by Novartis Pharma AG, Janssen Pharmaceuticals Inc., Eli Lilly, and Aptiv Solutions, which is an ICON plc company leading the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in Phase III trials. Both Pfizer’s and Roche’s decision to join the Consortium comes as more companies recognise the value of adaptive design in improving decision making in exploratory development.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Roche
ICON
Pfizer Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES